Denali Therapeutics
DNLINASDAQTransport vehicle blood-brain barrier delivery platform
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.
text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from
Key figures from SEC filings
Upcoming catalysts
Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.
BIIB122 LRRK2-PD: BIIB122 in LRRK2-associated Parkinson disease — primary completion
2027-03
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
COMPASS: Tividenofusp alfa in Mucopolysaccharidosis type II (Hunter syndrome) — primary completion
2027-12
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
DNL126: DNL126 in Mucopolysaccharidosis type IIIA (Sanfilippo A) — primary completion
2028-08
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| DNL310 | Hunter syndrome | Phase 2 | Not disclosed | ▼ |
| TAK-594/DNL593 | frontotemporal dementia with progranulin mutation | Phase 1 | Not disclosed | ▼ |
| BIIB122 partnership economics | Parkinson disease | Phase 2 | Not disclosed | ▼ |
Analysis
Comparable companies
Sponsored
Get premium DNLI analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you